Log in

NASDAQ:EVOKEvoke Pharma Stock Price, Forecast & News

$2.54
+0.22 (+9.48 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.27
Now: $2.54
$2.75
50-Day Range
$1.17
MA: $1.67
$2.61
52-Week Range
$0.50
Now: $2.54
$2.79
Volume1.41 million shs
Average Volume722,953 shs
Market Capitalization$62.74 million
P/E RatioN/A
Dividend YieldN/A
Beta2.03
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California.
Read More
Evoke Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.73 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EVOK
CUSIPN/A
Phone858-345-1494

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.18 per share

Profitability

Net Income$-7,130,000.00

Miscellaneous

Employees6
Market Cap$62.74 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive EVOK News and Ratings via Email

Sign-up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter.

Evoke Pharma (NASDAQ:EVOK) Frequently Asked Questions

How has Evoke Pharma's stock been impacted by COVID-19 (Coronavirus)?

Evoke Pharma's stock was trading at $1.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EVOK stock has increased by 128.8% and is now trading at $2.54. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Evoke Pharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evoke Pharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Evoke Pharma.

When is Evoke Pharma's next earnings date?

Evoke Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Evoke Pharma.

How were Evoke Pharma's earnings last quarter?

Evoke Pharma Inc (NASDAQ:EVOK) posted its earnings results on Tuesday, May, 12th. The specialty pharmaceutical company reported ($0.07) EPS for the quarter, missing the Zacks' consensus estimate of ($0.05) by $0.02. View Evoke Pharma's earnings history.

What are Wall Street analysts saying about Evoke Pharma stock?

Here are some recent quotes from research analysts about Evoke Pharma stock:
  • 1. According to Zacks Investment Research, "Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. " (1/4/2020)
  • 2. HC Wainwright analysts commented, "Valuation methodology and risks. We remain in a holding pattern until further clarity is obtained regarding the issues raised in the CRL and the degree to which they can be addressed near-term, as well as the timeline to potential resubmission of the Gimoti NDA and possible regulatory approval of the drug." (8/9/2019)

Has Evoke Pharma been receiving favorable news coverage?

Media headlines about EVOK stock have been trending positive this week, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Evoke Pharma earned a daily sentiment score of 3.0 on InfoTrie's scale. They also assigned news coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news aboutEvoke Pharma.

Are investors shorting Evoke Pharma?

Evoke Pharma saw a decline in short interest in April. As of April 30th, there was short interest totaling 100,900 shares, a decline of 25.1% from the April 15th total of 134,700 shares. Based on an average trading volume of 157,000 shares, the short-interest ratio is presently 0.6 days. Currently, 0.5% of the shares of the company are sold short. View Evoke Pharma's Current Options Chain.

Who are some of Evoke Pharma's key competitors?

What other stocks do shareholders of Evoke Pharma own?

Who are Evoke Pharma's key executives?

Evoke Pharma's management team includes the following people:
  • Mr. David A. Gonyer, Co-Founder, CEO, Pres & Director (Age 55)
  • Mr. Matthew J. D'Onofrio, Co-Founder, Chief Bus. Officer, Exec. VP, Treasurer & Sec. (Age 49)
  • Dr. Marilyn R. Carlson, Chief Medical Officer (Age 71)

What is Evoke Pharma's stock symbol?

Evoke Pharma trades on the NASDAQ under the ticker symbol "EVOK."

Who are Evoke Pharma's major shareholders?

Evoke Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Cetera Advisor Networks LLC (0.12%) and State of Michigan Retirement System (0.00%). View institutional ownership trends for Evoke Pharma.

Which major investors are selling Evoke Pharma stock?

EVOK stock was sold by a variety of institutional investors in the last quarter, including State of Michigan Retirement System. View insider buying and selling activity for Evoke Pharma.

Which major investors are buying Evoke Pharma stock?

EVOK stock was bought by a variety of institutional investors in the last quarter, including Cetera Advisor Networks LLC. View insider buying and selling activity for Evoke Pharma.

How do I buy shares of Evoke Pharma?

Shares of EVOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Evoke Pharma's stock price today?

One share of EVOK stock can currently be purchased for approximately $2.54.

How big of a company is Evoke Pharma?

Evoke Pharma has a market capitalization of $62.74 million. The specialty pharmaceutical company earns $-7,130,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Evoke Pharma employs 6 workers across the globe.

What is Evoke Pharma's official website?

The official website for Evoke Pharma is www.evokepharma.com.

How can I contact Evoke Pharma?

Evoke Pharma's mailing address is 420 STEVENS AVENUE SUITE 370, SOLANA BEACH CA, 92075. The specialty pharmaceutical company can be reached via phone at 858-345-1494 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.